News

Arzerra challenges obinutuzumab
Enlarge image

BusinessDenmarkUKSwitzerland

Arzerra challenges obinutuzumab

31.05.2013 - Genmab's and GSK's CD20 antibody ofatumumab challenges Roches
glyco-optimised obinutuzumab as treatment for CCL patients.

According to data presented by the Danish-British partnership, a combination  therapy of ofatuzumab (Arzerra) and chlorambucil significantly improved median progression-free survival of patients with chronic lymphocytic leukaemia (CLL). Patients treated with the combination lived 22.4 months on average without the disease worsening. That is 9.3 months more than in patients receiving the chemotherapeutic alone (13.1 months; Hazard Ratio 0.57; p<0.001).

Two weeks prior to that, Roche had also met the primary endpoint of a Phase  III study demonstrating a 12 months PFS benefit (23 months vs 10.9 months, HR=0.14, 95% CI 0.09-0.21, p  <.0001) of a combination of obinutuzumab + chlorambucil compared to  chemotherapy alone.

According to Genmab, serious adverse events were in the expected range with 3% of serious infusion reactions. Although not being statistically significant at this point in time, Roche published data indicating a higher rate of first-contact infusion reactions than observed after injections of the company's blockbuster rituximab.CLL is the most common form of leukaemia in adults. At present, no curative therapy is available.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/arzerra-challenges-obinutuzumab.html

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.94 EUR2.17%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.15 EUR45.9%
  • STRATEC BIOMEDICAL48.50 EUR21.7%

FLOP

  • BIOFRONTERA2.52 EUR-13.1%
  • CO.DON2.51 EUR-8.7%
  • ADDEX3.07 CHF-7.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 22.11.2014